Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP-HFpEF: semaglutide 2.4 mg once weekly in obesity-related HFpEF
MOH_2020-12-27_009487Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and obesity comparing Semaglutide with Placebo (2 arms). Primary endpoint: Heart failure symptoms and daily functioning. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on MOH_2020-12-27_009487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-27_009487.